Srdan Verstovsek, MD, PhD, discusses the role of ruxolitinib in patients with polycythemia vera.
Srdan Verstovsek, MD, PhD, director of the Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasms at The University of Texas MD Anderson Cancer Center, discusses the role of ruxolitinib (Jakafi) in patients with polycythemia vera (PV), a myeloproliferative neoplasm of the bone marrow.
The standard of care for patients with PV who are at high risk of thrombosis is hydroxyurea (Hydrea), a mild chemotherapy. However, Verstovsek says this does not work with all patients; about 20% of patients will develop an intolerance or resistance to the treatment.
Leveraging ctDNA to Predict Response in Patients With Myeloma Receiving CAR T Cells
March 20th 2023In an interview with Targeted Oncology, Hitomi Hosoya, MD, discussed the potential use of ctDNA in the myeloma space, including its ability to sequence BCMA-targeted therapies and reduce the need for bone marrow exams.
Read More
AI Continues to Push the Field of Radiation Oncology Forward
March 19th 2023In an interview with Targeted Oncology, Matthew Manning, MD, FASTRO, discussed the many radiation oncology tasks that have been improved with AI and its prospective utility in cancer diagnosis and treatment decisions.
Read More
Molecular Targets Making Headway in Pediatric Thyroid Cancer Research
March 16th 2023In an interview with Targeted Oncology, Aime T. Franco, PhD, discussed the molecular landscape of pediatric patients with thyroid cancer and the presentation she gave at the 91st Annual Meeting of the American Thyroid Association.
Read More
2 Clarke Drive
Cranbury, NJ 08512